Compass Pathways stock falls on Phase 3 trial data release

Compass Pathways shares fell 11% premarket after releasing 26-week Phase 3 data for COMP360 in treatment-resistant depression: 39% of patients in the 25 mg arm achieved a clinically meaningful MADRS reduction by week 6 (vs 25% in the earlier COMP005 single-dose study), with durability through week 26. Remission occurred in nearly 30% of week-6 responders after retreatment, while serious adverse events were relatively low (5.7% in the 25 mg arm over 26 weeks). The company is targeting a rolling NDA submission and expects a COMP360 launch in H1 2027, pending FDA/DEA approval and DEA rescheduling.

Analysis

CMPS is getting a higher probability of eventual approval, but not an immediate de-risking of the stock. The important incremental read is not efficacy in isolation; it is that repeat-dosing appears to support a plausible maintenance model, which matters for payer math and clinic utilization. That said, the market will still discount the business hard until the FDA/DEA path is visibly de-risked, because the first monetizable launch is still far away and the company remains a long-duration regulatory asset rather than a near-term revenue story.

The second-order winner, if the thesis holds, is the broader psychedelic infrastructure stack: clinic operators, care-delivery partners, and any company positioned to own training, monitoring, or post-dose follow-up. The main loser is the bear case that COMP360 is a one-and-done science project; these data improve the odds of a sustainable treatment paradigm, which should pressure weaker peers in the space that lack comparable late-stage evidence. The contrarian issue is commercial friction: a supervised, multi-visit regimen may cap margin expansion even if approval arrives, so approval risk may fall faster than reimbursement and adoption risk.

For NVDA, any weakness tied to the separate DeepSeek/custom-chip narrative is likely a trading signal, not a fundamental break, unless it is confirmed by hyperscaler capex or margin commentary over the next 1-3 months. The key falsifier for the CMPS bull case is any FDA complete response / delay, DEA rescheduling slippage, or evidence that safety/retreatment complexity makes uptake uneconomic.

Key Decisions for Investors

• Tactically add CMPS on weakness only, sized as a binary regulatory position; best risk/reward is into the July 7 webinar or after any follow-up FDA commentary, not on the opening print.
• Pair long CMPS vs short ATAI over 3-6 months: CMPS has the cleaner late-stage read-through, while ATAI remains more dependent on earlier, harder-to-underwrite assets.
• Use a call-spread structure on CMPS for 6-12 months if available liquidity allows; upside is a re-rating on NDA/DEA progress, while defined premium limits downside from schedule risk.
• Do not trade NVDA off this article alone; only use weakness as an alert if it is joined by soft hyperscaler capex guidance or ASIC displacement evidence in the next earnings cycle.
• Set a hard thesis break on CMPS if FDA/DEA timing slips materially beyond the current path; that would likely compress any speculative premium and warrant cutting exposure.